Compare Nuwellis Inc (NUWE) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Quantumscape Corp — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Quantumscape Corp trades at $4.65 (market cap $2.78B). The key difference: Quantumscape Corp is far larger — about 1263.6× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 11,236,221). Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Quantumscape Corp for 37 Days on average.
| NUWE | QS | |
|---|---|---|
Market Cap | $2.20M | $2.78B |
Volume | 121,544 | 11,236,221 |
Sector | Health | Consumer Cyclical |
52-Week High | $146.65 | $18.44 |
52-Week Low | $0.68 | $4.52 |
Typical Hold Time | 26 Days | 37 Days |
Enterprise Value | -$1.52M | $1.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
QuantumScape (QS) trades at $4.52, down 2.8% today, reflecting ongoing investor skepticism about the solid-state battery developer's commercial timeline. The company remains pre-revenue with negative $435M net income in 2025, though it has beaten EPS estimates in two of the last three quarters. Technical indicators show bearish momentum with the stock trading near key support levels, while analyst sentiment remains cautious with 73% hold ratings.
QS faces significant execution risk with commercialization not expected until 2029, creating substantial uncertainty for investors. The stock trades at a discount to the $10.35 consensus target, offering potential upside if technology milestones are met, but requires high risk tolerance given the lengthy path to profitability and intense competition in battery technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
